Kumaraguru Raja
Stock Analyst at Brookline Capital
(n/a)
# 4,760
Out of 4,761 analysts
15
Total ratings
8.33%
Success rate
-51.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $1.40 | +542.86% | 1 | Dec 18, 2024 | |
| PALI Palisade Bio | Initiates: Buy | $38 | $0.94 | +3,928.84% | 1 | Nov 20, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $1.82 | +339.56% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $10.98 | +810.75% | 2 | May 30, 2024 | |
| HEPA Hepion Pharmaceuticals | Downgrades: Hold | n/a | $0.17 | - | 1 | Dec 7, 2023 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $1.56 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $0.79 | +18,983.97% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $3.96 | +278.79% | 1 | Jun 29, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $2.64 | +695.45% | 1 | Jan 31, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $40.25 | +123.60% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $31 | $0.57 | +5,312.96% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,360 | $1.25 | +268,700.00% | 1 | Sep 21, 2021 |
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $1.40
Upside: +542.86%
Palisade Bio
Nov 20, 2024
Initiates: Buy
Price Target: $38
Current: $0.94
Upside: +3,928.84%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $1.82
Upside: +339.56%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $10.98
Upside: +810.75%
Hepion Pharmaceuticals
Dec 7, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.17
Upside: -
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.56
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $0.79
Upside: +18,983.97%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $3.96
Upside: +278.79%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $2.64
Upside: +695.45%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $40.25
Upside: +123.60%
May 18, 2022
Maintains: Buy
Price Target: $29 → $31
Current: $0.57
Upside: +5,312.96%
Sep 21, 2021
Initiates: Buy
Price Target: $3,360
Current: $1.25
Upside: +268,700.00%